Compounds > 2-(4-bromo-2,5-dimethoxyphenyl)-n-((2-methoxyphenyl)methyl)ethanamine
Page last updated: 2024-11-12

2-(4-bromo-2,5-dimethoxyphenyl)-n-((2-methoxyphenyl)methyl)ethanamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cimbi-36: a PET radioligand; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9977044
CHEMBL ID3590188
SCHEMBL ID17287281
MeSH IDM000603286

Synonyms (25)

Synonym
1026511-90-9
25b-nbome
new nexus
unii-s6naa81phk
dea no. 7536
4-bromo-2,5-dimethoxy-n-((2-methoxyphenyl)methyl)benzeneethanamine
cimbi-36
nbome-2c-b
s6naa81phk ,
bom 2-cb
4-bromo-2,5-dimethoxy-n-(2-methoxybenzyl)phenethylamine
2-(4-bromo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine
2,5-dimethoxy-4-bromo-n-(2-methoxybenzyl)phenethylamine
benzeneethanamine, 4-bromo-2,5-dimethoxy-n-((2-methoxyphenyl)methyl)-
CHEMBL3590188
SCHEMBL17287281
AKOS027446431
4-bromo-2,5-dimethoxy-n-[(2-methoxyphenyl)methyl]benzeneethanamine
25-b-nbome
Q4632126
2-(4-bromo-2,5-dimethoxyphenyl)-n-[(2-methoxyphenyl)methyl]ethanamine
2-(4-bromo-2,5-dimethoxyphenyl)-n-[(2-methoxyphenyl)methyl]ethan-1-amine
DTXSID50907974
2-(4-bromo-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethan-1-amine
PD046561

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Administration of tracer doses of [11C]Cimbi-36 does not seem to be associated with unusual radiation burden or adverse clinical effects."( Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36.
Ettrup, A; Hansen, M; Holm, S; Knudsen, GM; Kristensen, JL; Madsen, J; Palner, M; Santini, MA; Svarer, C; Wasim, M, 2013)		0.39

Dosage Studied

ExcerptRelevanceReference
"Rats were dosed intraperitoneally with 3 mg/kg of Cimbi-36 and euthanized at t = 5, 10, 15, 30, 60 and 120 min post-injection."( Desorption Electrospray Ionization Mass Spectrometry Imaging of Cimbi-36, a 5-HT
Herth, MM; Jacobsen, SC; Janfelt, C; Kristensen, JL; Palner, M; Speth, NR; Xiong, M, 2021)		0.62
"DESI imaging from an in vivo dosing experiment showed distribution of the PET tracer remarkably similar to what was obtained by autoradiography of an in vitro incubation experiment, indicating that the obtained results represent actual binding to certain receptors in the brain."( Desorption Electrospray Ionization Mass Spectrometry Imaging of Cimbi-36, a 5-HT
Herth, MM; Jacobsen, SC; Janfelt, C; Kristensen, JL; Palner, M; Speth, NR; Xiong, M, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1232249Selectivity for human 5-HT2A receptor over rat 5-HT2C receptor by PDSP assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (84.62)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.86 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenethylamine
phenethylamine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7016. 2-phenylethylamine : A phenylethylamine having the phenyl substituent at the 2-position.		2.9810alkaloid;
aralkylamine;
phenylethylamine		Escherichia coli metabolite;
human metabolite;
mouse metabolite
4-iodo-2,5-dimethoxyphenylisopropylamine
4-iodo-2,5-dimethoxyphenylisopropylamine: RN given refers to unlabeled parent cpd without isomeric designation; a serotonin agonist. 2-(4-iodo-2,5-dimethoxyphenyl)-1-methylethylamine : An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.		2.1110amphetamines;
dimethoxybenzene;
organoiodine compound
fenfluramine
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.. fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.		2.5520(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
ketanserin
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.		3.4120aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		2.1510adamantanes;
polycyclic alkane
fluorobenzenes
Fluorobenzenes: Derivatives of BENZENE that contain FLUORINE.. monofluorobenzene : The simplest member of the class of monofluorobenzenes that is benzene carrying a single fluoro substituent.. fluorobenzenes : Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group.		2.5320monofluorobenzenesNMR chemical shift reference compound
psilocybin
Psilocybin: The major of two hallucinogenic components of Teonanacatl, the sacred mushroom of Mexico, the other component being psilocin. (From Merck Index, 11th ed). psilocybin : A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms").		3.620organic phosphate;
tertiary amino compound;
tryptamine alkaloid		fungal metabolite;
hallucinogen;
prodrug;
serotonergic agonist
altanserin
altanserin: structure given in first source; a radioligand for PET studies of serotonin S2 receptors		2.1310quinazolines
mdl 100907
Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.		2.8230
az10606120
AZ10606120: a P2X7 receptor antagonist		2.1510
piperidines
Piperidines: A family of hexahydropyridines.		2.5320
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.110
Aggression
Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.		02.1110